1
SOCRA Certification Evaluation Comprehensive
Review Examination Actual Exam 2026/2027
with Detailed Rationales | Complete Exam-Style
Questions | Pass Guaranteed – A+ Graded
Q1: According to ICH GCP E6(R2), which document must be signed and dated by
the investigator prior to the initiation of any trial procedures?
A. Protocol amendment form
B. Investigator's curriculum vitae
C. Statement of Investigator Form (1572) [CORRECT]
D. Financial disclosure form
Correct Answer: C
Rationale: Correct because the FDA Form 1572 (Statement of Investigator) is a
mandatory commitment document that must be signed and dated by the
investigator before any trial-related activities begin, establishing their agreement to
conduct the study according to applicable regulations and the protocol.
Q2: A subject experiences a stroke during a Phase III oncology trial. The event
results in hospitalization and is possibly related to the investigational product.
What is the maximum timeframe for the sponsor to report this to the FDA?
A. 7 calendar days
B. 10 calendar days
C. 15 calendar days [CORRECT]
D. 30 calendar days
,2
Correct Answer: C
Rationale: Correct because under 21 CFR 312.32, sponsors must report serious and
unexpected suspected adverse reactions (SUSARs) to the FDA within 15 calendar
days for fatal or life-threatening events, and non-life-threatening serious events
also require expedited reporting within this standard timeframe for IND safety
reports.
Q3: Which of the following constitutes an "unanticipated problem involving risks
to subjects or others" (UP) according to federal regulations?
A. A Grade 2 nausea event listed as common in the informed consent
B. A protocol deviation where a visit window was missed by 3 days
C. A device malfunction that caused subject harm not previously described in the
risk analysis [CORRECT]
D. A laboratory value outside normal range that was expected based on product
mechanism
Correct Answer: C
Rationale: Correct because an unanticipated problem involves any incident,
experience, or outcome that is unexpected, related or possibly related to
participation in research, and suggests greater risk of harm than was previously
known - a device causing unlisted harm meets all three criteria per 45 CFR 46 and
FDA guidance.
Q4: Under HIPAA Privacy Rule, which of the following is NOT considered a
covered entity?
A. Health plan
,3
B. Healthcare clearinghouse
C. Healthcare provider who transmits health information electronically
D. Academic researcher conducting chart reviews without patient care duties
[CORRECT]
Correct Answer: D
Rationale: Correct because HIPAA covered entities are specifically defined as
health plans, healthcare clearinghouses, and healthcare providers who transmit
protected health information in electronic form - researchers who do not provide
healthcare services are not automatically covered entities under 45 CFR 160.102.
Q5: During an IRB continuing review, the board determines that a study should be
suspended due to unexpected safety concerns. What is the required timeline for
notifying the sponsor and FDA?
A. Within 5 working days
B. Immediately, but no later than 5 working days [CORRECT]
C. Within 10 calendar days
D. Within 30 calendar days
Correct Answer: B
Rationale: Correct because IRBs must promptly report any suspension or
termination of approval to the investigator, sponsor, and FDA - regulatory
guidance specifies notification should occur immediately but no later than 5
working days following the decision per 21 CFR 56.108(b)(1).
Q6: A clinical research coordinator discovers that the principal investigator failed
to sign the informed consent form for three subjects enrolled last month. This is
classified as:
, 4
A. Minor protocol deviation
B. Major protocol deviation [CORRECT]
C. Serious breach of GCP
D. Administrative error only
Correct Answer: B
Rationale: Correct because failure to obtain proper informed consent
documentation from the investigator is a major deviation affecting subject rights
and welfare - it represents a significant GCP violation requiring immediate
corrective action and potentially reportable to the IRB as a compliance issue.
Q7: According to 21 CFR Part 50, informed consent shall be documented using:
A. Verbal consent only when approved by IRB
B. A written consent form signed by the subject or legally authorized
representative [CORRECT]
C. Electronic signature with witness verification only
D. Oral consent documented in source notes
Correct Answer: B
Rationale: Correct because 21 CFR 50.27 requires that informed consent be
documented by use of a written consent form approved by the IRB and signed and
dated by the subject or the subject's legally authorized representative at the time of
consent.
Q8: Which phase of drug development primarily assesses dose-range finding and
preliminary safety?
SOCRA Certification Evaluation Comprehensive
Review Examination Actual Exam 2026/2027
with Detailed Rationales | Complete Exam-Style
Questions | Pass Guaranteed – A+ Graded
Q1: According to ICH GCP E6(R2), which document must be signed and dated by
the investigator prior to the initiation of any trial procedures?
A. Protocol amendment form
B. Investigator's curriculum vitae
C. Statement of Investigator Form (1572) [CORRECT]
D. Financial disclosure form
Correct Answer: C
Rationale: Correct because the FDA Form 1572 (Statement of Investigator) is a
mandatory commitment document that must be signed and dated by the
investigator before any trial-related activities begin, establishing their agreement to
conduct the study according to applicable regulations and the protocol.
Q2: A subject experiences a stroke during a Phase III oncology trial. The event
results in hospitalization and is possibly related to the investigational product.
What is the maximum timeframe for the sponsor to report this to the FDA?
A. 7 calendar days
B. 10 calendar days
C. 15 calendar days [CORRECT]
D. 30 calendar days
,2
Correct Answer: C
Rationale: Correct because under 21 CFR 312.32, sponsors must report serious and
unexpected suspected adverse reactions (SUSARs) to the FDA within 15 calendar
days for fatal or life-threatening events, and non-life-threatening serious events
also require expedited reporting within this standard timeframe for IND safety
reports.
Q3: Which of the following constitutes an "unanticipated problem involving risks
to subjects or others" (UP) according to federal regulations?
A. A Grade 2 nausea event listed as common in the informed consent
B. A protocol deviation where a visit window was missed by 3 days
C. A device malfunction that caused subject harm not previously described in the
risk analysis [CORRECT]
D. A laboratory value outside normal range that was expected based on product
mechanism
Correct Answer: C
Rationale: Correct because an unanticipated problem involves any incident,
experience, or outcome that is unexpected, related or possibly related to
participation in research, and suggests greater risk of harm than was previously
known - a device causing unlisted harm meets all three criteria per 45 CFR 46 and
FDA guidance.
Q4: Under HIPAA Privacy Rule, which of the following is NOT considered a
covered entity?
A. Health plan
,3
B. Healthcare clearinghouse
C. Healthcare provider who transmits health information electronically
D. Academic researcher conducting chart reviews without patient care duties
[CORRECT]
Correct Answer: D
Rationale: Correct because HIPAA covered entities are specifically defined as
health plans, healthcare clearinghouses, and healthcare providers who transmit
protected health information in electronic form - researchers who do not provide
healthcare services are not automatically covered entities under 45 CFR 160.102.
Q5: During an IRB continuing review, the board determines that a study should be
suspended due to unexpected safety concerns. What is the required timeline for
notifying the sponsor and FDA?
A. Within 5 working days
B. Immediately, but no later than 5 working days [CORRECT]
C. Within 10 calendar days
D. Within 30 calendar days
Correct Answer: B
Rationale: Correct because IRBs must promptly report any suspension or
termination of approval to the investigator, sponsor, and FDA - regulatory
guidance specifies notification should occur immediately but no later than 5
working days following the decision per 21 CFR 56.108(b)(1).
Q6: A clinical research coordinator discovers that the principal investigator failed
to sign the informed consent form for three subjects enrolled last month. This is
classified as:
, 4
A. Minor protocol deviation
B. Major protocol deviation [CORRECT]
C. Serious breach of GCP
D. Administrative error only
Correct Answer: B
Rationale: Correct because failure to obtain proper informed consent
documentation from the investigator is a major deviation affecting subject rights
and welfare - it represents a significant GCP violation requiring immediate
corrective action and potentially reportable to the IRB as a compliance issue.
Q7: According to 21 CFR Part 50, informed consent shall be documented using:
A. Verbal consent only when approved by IRB
B. A written consent form signed by the subject or legally authorized
representative [CORRECT]
C. Electronic signature with witness verification only
D. Oral consent documented in source notes
Correct Answer: B
Rationale: Correct because 21 CFR 50.27 requires that informed consent be
documented by use of a written consent form approved by the IRB and signed and
dated by the subject or the subject's legally authorized representative at the time of
consent.
Q8: Which phase of drug development primarily assesses dose-range finding and
preliminary safety?
